All NeuroSense Therapeutics (NRSN) 2025 shareholder meeting resolutions pass

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. reports that it held its Annual General Meeting of Shareholders on September 25, 2025. All resolutions presented at the meeting, as described in the company’s earlier Notice and Proxy Statement furnished on Form 6-K on August 21, 2025, were approved by shareholders. The company also states that this Form 6-K is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, meaning the information in this report becomes part of those securities registration documents.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2025

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

NeuroSense Therapeutics Ltd.

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9- 7996183
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Annual Meeting of Shareholders

On September 25, 2025, NeuroSense Therapeutics Ltd. (the “Company”) held its Annual General Meeting of Shareholders (the “Meeting”). At the Meeting, all proposed resolutions, as further detailed in the Company’s Notice and Proxy Statement furnished on Form 6-K to the Securities and Exchange Commission on August 21, 2025, were approved by shareholders.

This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File No. 333-269306, 333-260338, 333-283656 and 333-284051), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: September 25, 2025	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2

FAQ

What did NeuroSense Therapeutics Ltd. (NRSN) announce in this Form 6-K?

NeuroSense Therapeutics Ltd. announced that it held its Annual General Meeting of Shareholders on September 25, 2025, and that all resolutions proposed at the meeting were approved by shareholders.

Were all proposals approved at NeuroSense Therapeutics Ltd.’s 2025 Annual General Meeting?

Yes. The company states that all proposed resolutions set out in the Notice and Proxy Statement furnished on Form 6-K on August 21, 2025 were approved by shareholders at the Annual General Meeting.

How does this Form 6-K affect NeuroSense Therapeutics Ltd.’s existing registration statements?

The report states that this Form 6-K is incorporated by reference into NeuroSense Therapeutics Ltd.’s registration statements on Form S-8 (File No. 333-262480) and Form F-3 (File Nos. 333-269306, 333-260338, 333-283656 and 333-284051), becoming part of those documents from the date of submission.

Which SEC forms are referenced in this NeuroSense Therapeutics Ltd. (NRSN) filing?

The filing references Form 6-K for the current report, and states it is incorporated by reference into the company’s Form S-8 and multiple Form F-3 registration statements.

Who signed the NeuroSense Therapeutics Ltd. Form 6-K related to the 2025 Annual Meeting?

The Form 6-K was signed on behalf of NeuroSense Therapeutics Ltd. by Alon Ben-Noon, the company’s Chief Executive Officer, dated September 25, 2025.

Where can investors find the detailed resolutions for NeuroSense Therapeutics Ltd.’s 2025 Annual Meeting?

The detailed resolutions are described in the company’s Notice and Proxy Statement that were previously furnished to the SEC on Form 6-K on August 21, 2025.